Amylyx Pharmaceuticals will announce topline results from its Phase 3 Lucidity clinical trial of Avexitide in post-bariatric hypoglycemia on 18 August 2026, and will host a conference call and audio webcast at 8:00 a.m. ET.
The live webcast will be available through the company’s investor events and will be archived for 90 days.
Amylyx is listed on Nasdaq under the ticker AMLX. According to the company, it is focused on four investigational therapies across endocrine conditions and neurodegenerative diseases. The company claims it pursues opportunities with urgency, rigorous science and unwavering commitment to the communities it serves.
